WVU Study Uncovers Hidden, Potentially Targetable Gene Fusions in Glioblastoma

Glioblastomas remain among the most aggressive and challenging brain cancers to treat. A landmark study led by Sonikpreet Aulakh, MD, at the WVU Cancer Institute has advanced glioblastoma research by uncovering hidden, potentially targetable gene fusions in approximately 9% of Glioblastomas through the comprehensive analysis of the largest transcriptomic datasets available to date.

Her work demonstrates that these fusions—primarily involving genes such as FGFR3, MET, EGFR, NTRK2, and PDGFRA—may define a distinct molecular subset of Glioblastoma, revealing actionable vulnerabilities often missed by traditional profiling methods. This discovery provides fresh insights to guide personalized treatment pathways, refine prognostic assessments, and highlight opportunities for targeted therapies against these rare alterations.

The findings strongly advocate innovative multi-arm clinical trial designs to efficiently screen and evaluate targeted agents in these molecularly defined subgroups.

The full study can be found here.